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Abstract

Obesity is a growing epidemic in the United States with significant co-morbidities. NonAlcoholic Fatty Liver Disease (NAFLD) is a prevalent manifestation of obesity that can lead to
cirrhosis. Roux-en-Y gastric bypass (RYGB) results in substantial long-term weight loss and
resolution of obesity-related metabolic diseases. There appears to be a weight-independent
molecular mechanism for the improvement of diabetes mellitus and NAFLD after RYGB, which
is poorly understood. Obesity is associated with chronic inflammation that accompanies the
hepatic steatosis. Through unknown mechanisms, RYGB in humans increases serum levels of the
fat-derived adipocytokine, adiponectin. Adiponectin (an anti-inflammatory cytokine) is known to
have a protective role in animal models of alcoholic and non-alcoholic liver injury. Clarifying the
link in signaling between NAFLD, inflammatory signaling, and lipogenesis would enhance our
insight into the pathogenesis of the metabolic syndrome and warrants further exploration. The
accompanying resolution of metabolic disorders after gastric bypass gives a unique opportunity to
elucidate the associated mechanisms and molecular pathways.
We hypothesized that RYGB would attenuate obesity-induced steatosis and inflammatory
changes in the livers of obese rats. These investigations would lend insight into alterations in the
hepatic fatty acid synthesis and fatty acid oxidation signaling pathways after gastric bypass. We
set out to test our hypothesis in obese rats via three specific aims: (1) Establish a rat model of
RYGB to study obesity-related liver injury, (2) Investigate the mechanisms through which RYGB
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improves inflammation, (3) Investigate the mechanisms through which RYGB improves hepatic
steatosis.
Rat models for obesity and RYGB may be used to elucidate mechanistic pathways and
develop less invasive treatments for obesity and its related co-morbidities. However, the rat model
for RYGB is difficult to successfully reproduce and is frequently associated with high operative
mortality. Our first challenge was to establish this rat model of RYGB so that we could use it in
future studies. Initially, we followed published protocols for rat RYGB with minimal success.
Subsequently, we identified several key factors that improved survival, developing a model with
consistent survival of over 90% and tracking our outcomes. To help other researchers, we detailed
techniques to improve survival of these obese rats undergoing RYGB in order to more effectively
establish this model. We further demonstrated that our rat RYGB model had the necessary
endpoints of sustained weight loss and resolution of steatosis. This rat model of RYGB provides
a valuable opportunity to further elucidate the pathogenesis of NAFLD to pave the road for future
therapies for this disease.
Next, we used this rat RYGB model to investigate the mechanisms through which RYGB
improves inflammation. Obesity is associated with chronic inflammation and RYGB is thought
to improve this. Adiponectin has anti-inflammatory properties and is increased with weight loss.
Tumor necrosis factor (TNF)-α is a pro-inflammatory cytokine that negatively regulates
adiponectin. We hypothesized that the weight loss and steatosis resolution after RYGB would
alter the interplay of TNF-α and adiponectin signaling in the postoperative period. Using our rat
model of RYGB, we examined TNF-α and adiponectin signaling in serum, adipose tissue, and
liver tissue. Contrary to what we were expecting, we found that RYGB in obese rats did not
increase anti-inflammatory adiponectin signaling in the immediate postoperative period but was
x

associated with decreased pro-inflammatory TNF-α signaling in the adipose tissue. During this
period, pro-inflammatory signaling might play a more important role than adiponectin.
Notwithstanding, the results of this present study demonstrate exciting and novel changes in the
balance of pro-inflammatory and anti-inflammatory signaling after RYGB and lay the framework
for future investigations into these metabolic changes after gastric bypass.
Finally, we investigated the mechanisms through which RYGB improves hepatic steatosis.
We hypothesized that either lipogenesis would be down-regulated or fatty acid oxidation would
be upregulated or both of these would occur. We aimed to examine major cell signaling pathways
of hepatic lipogenesis and fatty acid oxidation using our rat model of RYGB. We confirmed that
RYGB resolved steatosis, reduced hepatic triglycerides, and downregulated hepatic lipogenesis
controlled by multiple components in the stearoyl-CoA desaturase (SCD) 1 signaling pathway.
This novel finding is important since SCD1 plays a pivotal role in triglyceride synthesis. In this
model, the SIRT1-PPARα/PGC1α signaling pathway and fatty acid oxidation were not
upregulated at 9 weeks after RYGB. Whether this fatty acid oxidation pathway plays a greater
role at a different time point after RYGB needs to be determined to assess the temporal relationship
between gastric bypass and fatty acid oxidation changes.

These studies demonstrate the

downregulation of multiple components of the triglyceride synthesis pathway, which warrant
further investigation to increase our insight into the impact of gastric bypass on NAFLD. These
novel findings indicate that RYGB improves steatosis by downregulating lipogenesis without
upregulating fatty acid oxidation in obese rats.

xi

Chapter 1:
Introduction

1.1 Obesity epidemic
Obesity is a growing epidemic, with over 26% of the United States population being
classified as obese and an additional 37% classified as overweight [1]. Obesity is associated with
co-morbidities including hypertension, type 2 diabetes, hyperlipidemia, obstructive sleep apnea,
heart disease, stroke, asthma, osteoarthritis, depression, and several forms of cancer [2]. While
diet therapy is relatively ineffective in the longterm treatment of obesity, bariatric surgery has been
shown to be 95% effective in achieving sustained weight loss [2]. Obesity-related co-morbidities
understandably improve or resolve after weight loss from bariatric surgery, however, two
observations have stimulated investigations into a secondary mechanism independent of weight
loss that may be responsible for improvement in the metabolic disorders. First, type 2 diabetes is
found to resolve often within days of gastric bypass, before any significant weight loss has
occurred [2]. This effect is not observed after gastric banding, which does not bypass the proximal
small bowel and requires the concomitant weight loss to see improvement in diabetes. Second,
the resolution of diabetes is more prevalent after gastric bypass (84%) than after gastric banding
(48%), indicating that the bypass of the proximal small bowel may contribute an additional
molecular mechanism for improvement of the metabolic disorders [2]. Whether new receptors are
triggered by the delivery of high concentrated foods to the distal bowel (hindgut theory) or
receptors in the duodenum are no longer triggered because food no longer passes through the
1

duodenum (foregut theory), it is clear that alterations in cell signaling and not just weight loss
appear to be responsible for improvements in the metabolic diseases of obesity.
Obesity-related liver injury, known as Non-Alcoholic Fatty Liver Disease (NAFLD), is
one of the important consequences of the metabolic changes of obesity, with at least 31% of
bariatric surgery patients exhibiting steatohepatitis, cirrhosis or severe fibrosis in routine liver
biopsies [3]. NAFLD has a nationwide prevalence of 17-33% [4] and preliminary data suggests
that Roux-en-Y gastric bypass (RYGB) improves these hepatic abnormalities [5]. Surgicallyinduced weight loss remains the most effective anti-obesity intervention. The accompanying
resolution of comorbidities gives us a unique opportunity to clarify the mechanisms and molecular
pathways that are affected by weight loss and, in particular, by RYGB.

1.2 Non-Alcoholic Fatty Liver Disease
NAFLD is a common manifestation of obesity and is linked to the metabolic syndrome
through a complex interplay of hepatic glucose and lipid metabolism, skeletal muscle glucose
uptake, and peripheral insulin resistance [6]. Histological features of NAFLD range from
steatosis (excess lipid accumulation in liver) or steatohepatitis (NASH; inflammatory infiltrates),
to fibrosis or cirrhosis. In our clinical series of 660 consecutive bariatric patients who underwent
routine intraoperative liver biopsy, only 4% had normal liver histology while 22% exhibited
steatohepatitis, and 9% demonstrated fibrosis or cirrhosis [3]. We have follow-up data that
showing that biopsies in 100 of these patients after RYGB demonstrate substantial improvement
in liver histology, but the mechanism of this improvement is yet unknown.
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1.3 Obesity and Chronic Inflammation
Metabolic disorders, such as obesity, have been linked to inflammatory changes in adipose
tissue and liver. Obesity activates several signaling pathways that target pro-inflammatory genes
[7], upregulating toll-like receptor (TLR) 4, interleukin 1 receptor (IL-1R), protein kinase C
(PKC), nuclear factor kappa –B (NF-κB) and c-Jun N terminal kinase (JNK) in adipocytes,
hepatocytes and macrophages [8-10]. Hepatic steatosis induces 'inflammation' that results in local
and systematic insulin resistance via activation of NF-κB [11,12] and peroxisome proliferatoractivated receptor (PPAR)-γ [13]. Activation of upstream kinases, such as PKC-ζ/λ in livers of
obese mice induces insulin resistance via upregulation of sterol regulatory element binding protein
(SREBP) [14,15]. SREBP and carbohydrate response element binding protein (ChREBP) are two
transcription factors that are important in glucose and lipid metabolism and have a synergistic
effect on hepatic steatosis and insulin resistance in obese mice [16]. This evidence clearly links
obesity, liver injury, and diabetes.

1.4 Adiponectin
Adiponectin may be a key link in this chain of inflammation and injury. This fat-derived
adipocytokine, accounts for 0.01% of plasma proteins and is decreased in obese patients [17,18].
Adiponectin, which exhibits anti-inflammatory and anti-diabetic properties [19,20], improves
insulin-resistance by activating AMP-activated kinase (AMPK) in mice liver and skeletal muscle
[21]. In a model of alcohol-induced chronic liver injury and fatty liver, serum adiponectin and
hepatic adiponectin receptor (AdipoR)-2 mRNA and protein expression were increased in mice
fed a diet high in saturated fat. Upregulation of adiponectin and hepatic AdipoR2 were associated
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with activation of AMPK and PPARα/γ and led to prevention of hepatic lipid accumulation
(steatosis) and significant improvement in liver enzymes levels [22].
Adiponectin is released by fat cells and has anti-inflammatory, vasculoprotective and antidiabetic effects. Serum levels of adiponectin are decreased in patients with insulin resistance and
diabetes. Adiponectin levels in humans can be increased through RYGB [23] and have a protective
role in animal models of alcoholic and non-alcoholic liver injury [22]. Two adiponectin receptors
(AdipoR1 and AdipoR2) have been identified; AdipoR1 is expressed in skeletal muscle, whereas
AdipoR2 is predominantly expressed in the liver; its insulin-sensitizing effect seems to be
mediated by an increase in fatty-acid oxidation through activation of AMPK and PPAR [24].
Adiponectin exhibits its anti-inflammatory activities through interaction with
macrophages. Adiponectin inhibits TLR-mediated NF-κB signaling and cytokine production in
mouse peritoneal macrophages [25], induces the production of the anti-inflammatory cytokine IL10 in human monocytes [26] and attenuates LPS-stimulated production by rat Kupffer cells [27].
In mice with steatohepatitis, administration of adiponectin reduced steatosis, attenuated
inflammatory changes in the liver, and suppressed hepatic and serum levels of tumor necrosis
factor (TNF)-α [28]. Adiponectin increased after RYGB, coupled with the loss of fat mass
[23,29,30], and was associated with decrease in serum TNF-α [29]. Therefore, inflammation
appears to be regulated by an interplay of pro-inflammatory (TNF-α) and anti-inflammatory
(adiponectin) signaling.

1.5 Lipid metabolism
The two-hit theory of the pathogenesis of both alcoholic and non-alcoholic liver disease
relates a dysfunction in both lipid metabolism and oxidative stress. First, lipids accumulate in the
4

liver via increased lipogenesis and fat deposition or via decreased B-oxidation of fatty acids.
Metabolic and environmental stressors, (including oxidative stress related to steatosis) then appear
to activate Kupffer cells and finally hepatic stellate cells, leading to increased tissue remodeling
and fibrosis [31,32].
The degree of steatosis is related to the rates of both lipogenesis and fatty acid oxidation.
stearoyl-CoA desaturase (SCD) 1, fatty acid synthase (FAS), acetyl-CoA carboxylase (ACC), and
glycerol-3-phosphate acyltransferase (GPAT) 1 are prominent lipogenic enzymes which have been
shown to be upregulated in livers of obese mice. SCD1 is the rate-limiting catalyst in the synthesis
of monounsaturated fatty acids, a precursor for hepatic triglycerides [33]. Serum leptin is known
to negatively regulate hepatic SCD1 in mouse models [34]. SREBP1 and ChREBP are key nuclear
transcription factors regulating SCD1, FAS, ACC, and GPAT1 [33,35-37]. Additionally, the
nuclear transcription factor liver X receptor (LXR) α directly targets both SREBP1c and ChREBP
[33,38]. AMPK is a key regulator of cellular metabolism [39] and plays a critical role in both
lipogenesis (downregulating GPAT1) [35] and fatty acid oxidation (through upregulating PPAR
gamma coactivator (PGC) 1α and PGC1α targets) [40].
While the signaling for key lipogenic (SCD1, FAS, ACC, and GPAT1) and fatty acid
oxidation (AMPK, PGC1α) pathways has been studied using rodent models, the molecular
mechanisms by which surgically-induced weight loss exerts its lipid-lowering effects in the liver
remain unclear. It is expected that, because RYGB improves fatty liver, either lipogenesis will be
down-regulated or fatty acid oxidation will be upregulated or both of these will occur.

5

1.6 Oxidative stress
In fatty livers, excess lipid accumulation initiates oxidative stress that induces Kupffer cell
cytokine production and hepatocyte injury; subsequent activation of stellate cells by Kupffer cellderived cytokines leads to deposition of fibrous tissue (fibrosis) and disruption of tissue
remodeling (cirrhosis) [31]. Therefore lipid metabolism, oxidative stress, and inflammation are
all interrelated parts in the pathogenesis of NAFLD.

1.7 Gastric Bypass
In obese humans, RYGB increases serum adiponectin [23,41,42] and improves glucose
homoeostasis, lipid metabolism, and liver abnormalities [5,43-45]. Liver biopsies show resolution
of steatosis and significant improvement in steatohepatitis after successful weight loss from RYGB
[5,44,46-48].

1.8 Rodent Model of Obesity
Obesity is associated with steatosis and preliminary data in humans suggests that RYGB
improves manifestations of NAFLD [5]. While it is ideal to study molecular changes after RYGB
in humans, animal models can provide useful preliminary data with more controlled, shorter, and
less expensive studies which can be corroborated later with human studies. In order to validate a
diet-induced rodent model of NAFLD, we performed preliminary studies in mice and rats.

1.8.1 Obesity alters systemic inflammation
Mice fed high fat diet (HFD), demonstrated a significant increase in body weight and
steatosis (represented by increased hepatocellular ballooning and fatty deposition). These obese
6

mice had a significant reduction in serum levels of the anti-inflammatory cytokine, adiponectin,
when compared to regular diet controls [49].

1.8.2 Obesity induces hepatic inflammation
In livers of obese rats, proinflammatory signaling was upregulated with both mRNA and
protein of TLR4, IL-6, iNOS, and TNF-α increased, while IL-10 and PKC- ζ were similar to
controls. Similarly, nuclear translocation of NF-κB also increased, demonstrating increased
hepatic inflammation with obesity [49].

1.8.3 Obesity downregulates hepatic adiponectin signaling
High fat diet reduced mRNA and protein for adiponectin receptor-2 (AdipoR2) expression
in mice livers when compared to regular diet controls. AdipoR2 and PPARγ also co-localized
with F4/80, indicating that Kupffer cells are potential targets for adiponectin signaling and may be
the link between obesity and hepatic inflammation [49].

1.8.4 Obesity increases hepatic lipogenic signaling
In livers of obese mice SREBP1c (a nuclear transcription factor involved in lipogenesis)
mRNA and protein were increased compared to regular diet controls [49]. This preliminary data
demonstrates an obesity-induced increase in inflammatory and lipogenic signaling pathways in
rodent models.
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1.8.5 Rat model of RYGB
Rat and mouse models of diet-induced obesity both exhibit steatosis, however, due to small
size and increased metabolism the mouse model is extremely difficult to establish. To further
examine the molecular mechanisms by which RYGB improves NAFLD, it is valuable to establish
a rat model of RYGB with endpoints of sustained weight loss and resolution of steatosis.
A small preliminary study (n= 3-4 per group) confirmed that high fat diet for 14 weeks
induces obesity and increases body weight in male Sprague-Dawley rats (p<0.005 versus rats fed
regular diet). The rat model for RYGB is associated with high operative mortality by all published
accounts [50]. After several modifications of published protocols (described in chapter 2), we
successfully reproduced the rat model of RYGB. RYGB induced progressive and significant
weight loss in obese rats (p<0.01 versus sham). Obesity induced steatosis in rats with high fat diet
increasing hepatocyte fat content and ballooning. RYGB reduced steatosis compared to shamoperated rats. This preliminary data establishes this valuable rat model of RYGB for our group
and validates its usefulness as a model of NAFLD.

1.9 Conclusions
Clarifying the link in signaling between NAFLD, inflammatory signaling, and lipogenesis
would enhance our insight into the pathogenesis of the metabolic syndrome and warrants further
exploration.
Through unknown mechanisms, Roux-en-Y gastric bypass (RYGB) in humans improves
NAFLD and increases serum levels of the fat-derived adipocytokine, adiponectin. Adiponectin
(an anti-inflammatory cytokine) is known to have a protective role in animal models of alcoholic
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and non-alcoholic liver injury. The accompanying resolution of metabolic disorders after gastric
bypass provides the opportunity to investigate the associated mechanisms and molecular pathways.
We hypothesized that RYGB would attenuate obesity-induced steatosis and inflammatory
changes in the livers of obese rats. These investigations would lend insight into alterations after
RYGB in fatty acid synthesis and fatty acid oxidation signaling pathways, as well as quantify
changes in oxidative stress. We set out to test our hypothesis in obese rats via three specific aims:
(1) Establish a rat model of RYGB to study obesity-related liver injury, (2) Investigate the
mechanisms through which RYGB improves inflammation, (3) Investigate the mechanisms
through which RYGB improves hepatic steatosis.
This rat model of RYGB provides a unique opportunity to further elucidate the
pathogenesis of NAFLD to pave the road for future therapies for this disease.
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Chapter 2:
Developing a Rat Model of Roux-en-Y Gastric Bypass

2.1 Overview
The rat model of Roux-en-Y gastric bypass (RYGB) provides a unique opportunity to
further elucidate the pathogenesis of Non-Alcoholic Fatty Liver Disease (NAFLD) to pave the
road for future therapies for this disease. However, RYGB is a technically challenging procedure
and is associated with high operative mortality in rodents. We describe our techniques used to
improve survival of obese rats undergoing RYGB.
We introduced interventions to improve survival after RYGB including: 1) use of
inhalational anesthetic with streamlined procedure to reduce anesthetic time; 2) use of metabolic
cages to prevent rats from ingesting bedding and feces; 3) instituting a 12 hour preoperative fast
and a gradual advance to a solid diet over 1 week; 4) reducing the size of the gastric pouch and
enlarging the gastrojejunostomy to facilitate emptying; 5) minimizing manipulation of abdominal
structures. Body weights and survival were compared.
RYGB was undertaken in 18 consecutive rats according to published protocols (control)
and in 21 rats after the above interventions were introduced. Survival at 6 weeks postoperatively
increased from 11% to 86% after introducing our interventions. Survival was similar between
sham-operated rats (n = 8) and RYGB rats (n = 21). Body weight was lower postoperatively in rats
that underwent RYGB compared to sham-operated controls (p<0.001).
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Simple modifications in operative technique and perioperative care improved mortality of
RYGB in obese rats. Through these endeavors, we successfully established a rat model of RYGB
for the purpose of studying obesity-related liver injury. Lessons learned from our experience
should shorten the learning curve of establishing animal models of obesity and RYGB for other
researchers.

2.2 Introduction
Obesity is a growing epidemic and a major public health concern [1]. Roux-en-Y gastric
bypass (RYGB) results in substantial long-term weight loss and resolution of obesity-related
metabolic diseases [2]. The molecular mechanisms for improvement of diabetes mellitus and
hepatic steatosis after RYGB are poorly understood. Rat models for obesity and RYGB may be
used to elucidate mechanistic pathways and develop less invasive treatments for obesity and its
related co-morbidities. However, the rat model for RYGB is difficult to successfully reproduce
and is frequently associated with high operative mortality. While many researchers describe basic
methods of rat RYGB, additional details for how to develop the model can help avoid costly pitfalls
and delays.

Initially, we followed standard techniques for RYGB along with protocols as

published by others with minimal success [3-5]. Our mortality for RYGB in rats exceeded 85% in
the first 36 hours postoperatively. Subsequently, we identified several key factors that improved
survival. The protocol was adjusted accordingly and outcomes were tracked. We herein describe
techniques to improve survival of obese rats that undergo RYGB and to more effectively establish
the rat model of RYGB.

14

2.3 Materials and Methods
These studies were performed as part of a protocol approved by the Institutional Animal
Care and Use Committee of the University of South Florida (see Appendix 2). The University of
South Florida complies with all Public Health Service policies with regard to all provisions of the
Animal Welfare Act. The University of South Florida’s animal care and use program is AAALAC
accredited and is a USDA registered facility.

2.3.1 Induction of obesity
Four-week-old male Sprague-Dawley rats purchased from Harlan Laboratories (Harlan
Sprague Dawley, Inc., Indianapolis, IN, USA). Rats were maintained in sterile cages with
appropriate food, water, bedding, and cyclical lighting (12 hour light–dark cycle) and temperature
control (20-24C).
Animals were acclimated for 4 days on regular rat chow (6% fat by weight; Harlan Teklad
Global Diet 2018, Indianapolis, IN) and then baseline body weights are obtained. Rats were then
randomized to regular chow or high fat diet (60.3% of calories from fat; Harlan Teklad TD.06414,
Indianapolis, IN) and maintained on their respective diets for 14 to 16 weeks. High fat diet rats
that were greater than 500 grams (or the upper 50% of animals by weight) were designated as
obese and randomized to undergo either RYGB or sham operation.

2.3.2 Perioperative and anesthetic care
Animals were fasted the night prior to surgery for approximately 12 hours and were housed
in suspended wire mesh caging to allow feces and urine to fall through the rack and to prevent the
rats from eating waste or bedding. The rats were anesthetized with isoflurane using a calibrated
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vaporizer equipped with a device for properly scavenging waste anesthetic gas. An induction
chamber was used with an initial vaporizer flow rate of 3-5%. After induction, animals were
removed from the chamber and anesthesia was maintained using a rodent-specific nose cone
apparatus at the same flow rate. Ceftriaxone (25mg/kg) and Ketoprofen (5mg/kg) were given
subcutaneously.
The abdomen was shaved in a remote location prior to transfer to the operative field. The
abdomen was prepped and draped aseptically. Heating pads were used throughout the operation.
The isoflurane vaporizer flow rate was reduced to 1-2% after the abdominal incision was made.
The rats were monitored for signs of either pain or respiratory depression and the flow rate adjusted
accordingly.

2.3.3 Roux-en-Y gastric bypass
A 4 cm midline incision was made. Study-related biopsies (liver, abdominal wall muscle,
subcutaneous and omental adipose) were collected. Subsequently, peritoneal attachments to the
stomach were divided, with particular attention to the attachment between the posterior stomach
and the caudate lobe. The stomach was divided using a linear stapler (EndoGIA 45-2.5; Covidien,
New Haven, CT) thereby creating a small gastric pouch (20% of stomach). Care was taken to
avoid injury or outflow obstruction to the esophagus or duodenum. The proximal jejunum was
divided 10 cm distal to the Ligament of Treitz (corresponding to 15% of total jejunal-ileal length).
A 6 mm gastrotomy was made on the anterior surface of the pouch to gently empty any luminal
contents onto gauze. An end-to-side gastrojejunostomy was constructed using 6-0 Polypropylene
suture in a continuous manner. The jejunojejunostomy was constructed 10 cm distal to the
gastrojejunostomy with interrupted 6-0 Polypropylene. Handling of the abdominal structures was
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minimized by use of sterile cotton applicators instead of surgical forceps when possible. Salinesoaked gauze was used to keep the abdominal viscera moist throughout the procedure. 5 ml of
0.9% normal saline was administered intraperitoneally prior to closing the incision.

The

abdominal incision was closed with two layers of continuous 4-0 suture. An additional 5 ml of
0.9% normal saline was injected subcutaneously. Isoflurane was turned off after the incision was
closed. The rats regained consciousness within 2 minutes of the end of the procedure and were
monitored until no residual anesthetic effects were observed.

2.3.4 Sham operation
Sham operations were conducted with identical perioperative care and operative
conditions. Study-related biopsies were similarly collected after the abdominal incision was
made. Abdominal contents were mobilized and manipulated to parallel the RYGB procedure.
The abdominal incision was kept open until the mean anesthesia time for RYGB was reached.
Abdominal wound closure and normal saline administration were consistent with RYGB.

2.3.5 Postoperative care
The rats were singly housed in the suspended wire mesh cages for seven days, until the
resumption of a solid diet. Additional Ketoprofen was given every 8 to 12 hours, for up to 2 days
postoperatively as needed for pain.
Rats were given water ad libitum starting the morning after surgery and were started on
dilute liquid food (Ensure, Abbott Laboratories, Chicago, IL) the following day. The rats were
monitored and given additional doses of pain medications (for hunching posture, raised hair,
hypersensitivity) and extra subcutaneous 0.9% normal saline (for decreased urine output or poor
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oral intake) as needed. All rats were advanced to full strength liquid food when demonstrating
tolerance of dilute Ensure (Abbott Laboratories, Chicago, IL). By the seventh postoperative day
rats were resumed on solid food (high fat diet) and were returned to their regular cages and
bedding. Rats were observed daily for complications and weighed weekly.

2.3.6 Interventions and modification of established rodent RYGB protocols
While attempting to reproduce the rat model of RYGB using established protocols, we
were met with significant mortality. We made some “general modifications” to these published
protocols in an attempt to improve survival, with little benefit. We then implemented some
“specific modifications” with dramatic improvement in survival. In order to better understand
the impact of these modifications, we collected survival data for these groups, before and after
implementation of these “specific modifications”.

2.3.6.1 General modifications
The set of initial “general modifications” to published protocols were: (1)
changing to inhalational anesthetic (isofluorane) instead of intraperitoneal pentobarbital, (2)
streamlining procedures to minimize anesthesia exposure, (3) minimizing trauma to abdominal
structures by using cotton applicators instead of surgical forceps when possible.
These modifications were intended to reduce anesthesia-related complications and
generalized operative care. Postoperatively most rats regained consciousness but died within the
next 36 hours. This was an improvement, because we had occasionally had a rat not survive the
anesthetic. However, we were disappointed with these outcomes in 18 rats that underwent
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RYGB using only these “general modifications”. With this poor survival profile, it would be
challenging to study the metabolic improvements after RYGB.

2.3.6.2 Specific modifications
The set of “specific modifications” to published protocols were: (1) using
suspended wire mesh caging to house rats perioperatively, (2) changing perioperative diet with a
slower return to solid food, (3) construction of a smaller gastric pouch and larger
gastrojejunostomy.
An additional consecutive 21 rats underwent RYGB with these “specific
modifications”, with immediate improved survival outcomes.

2.3.6.3 Evaluating the impact of the modification of rodent RYGB protocols
In order to demonstrate the significance of these modifications to our protocol we
retrospectively reviewed our data. We excluded the first 8 rats to eliminate the confounding
nature of the “technical” learning curve. Of note, some of these initial rats underwent RYGB
before the general modifications had been uniformly instituted, so there was a learning curve for
anesthesia administration involved as well with these rats.
For the purpose of this study, the next 18 consecutive rats underwent RYGB using
only the “general modifications”. In the second group, another 21 consecutive rats underwent
RYGB using the “specific modifications”.
Survival data was recorded for both groups, to note the impact of implementing
these “specific modifications”. Survival was noted for 1 and 6 weeks postoperatively. Sham
operations were performed as controls using the “specific modifications” as they applied.
19

Weekly weight data was obtained to demonstrate the effectiveness of the model. Rats fed a
regular rat diet for the same period of time were included as a weight reference.

2.3.7 RYGB model endpoints
For the rat RYGB model to be an effective tool to use for investigating changes after
RYGB there needed to be substantial and sustained weight loss and histological evidence of
resolving steatosis to be representative of changes in humans after RYGB. Body weights were
measured serially on a weekly basis, with average group weights plotted against time after the
operation. Based on preliminary data and paralleling typical human weight curves after RYGB,
the rats should lose substantial weight for the first few weeks after RYGB and then regain a
small amount of weight, finally plateauing at about 6 weeks after RYGB. Sham-operated
animals should lose a small amount of weight immediately after the operation but quickly regain
that weight and continue to gain weight on their prior growth curve.
Liver sections were processed for hematoxylin and eosin (H&E) and oil red staining to
evaluate for steatosis. Imaging software was used to quantify fat deposition. Researchers were
blinded to animal identity when assessing liver histology.

2.3.8 Statistical analysis
All data are presented as mean ± standard deviation. The 2-tailed t-test was used when
comparing two separate groups (as in RYGB and sham groups); p < 0.05 considered significant.
For serial time points (as in preoperative and postoperative), the paired t-test was utilized.
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2.4 Results

2.4.1 Operative times
Using “general modifications”, we decreased anesthesia time (induction to recovery) from
120 ± 25min to 71 ± 4min (p<0.05). Anesthesia times for sham operations were maintained as
close to RYGB times as possible and were not statistically different (74 ± 10min; p=0.47 vs.
RYGB).

2.4.2 Mortality and morbidity of RYGB
RYGB was performed on 18 consecutive rats using the “general modifications”. All rats
recovered from the anesthesia and appeared to be doing well, but almost all these rats died within
the first 36 hours of surgery. Survival in the first week was 11% and did not change at 6 weeks
postoperatively. A necropsy was performed on each rat that died. The cause of death often could
not be determined but occasionally there was either a full stomach or a questionable leak at the
gastrojejunostomy. Of note, while all the rats were fasted overnight preoperatively, almost all of
them would still have a stomach full of bedding or other material at the time of the operation.
When an attempt was made to gently empty the contents of the stomach onto a gauze before
performing the RYGB, the rats seemed more likely to develop an anastomotic leak postoperatively.
When the contents of the stomach were left in place, the rats more frequently were found with a
dilated pouch and gastric outlet obstruction at necropsy.
Based on the above observations and discussions with other investigators using the rodent
RYGB model, we developed the “specific modifications” previously listed. RYGB was then
undertaken on 21 consecutive rats using these additional “specific modifications”. Survival
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increased immediately and dramatically (Table 2.1, Fig. 2.1) using this new protocol. Survival
after RYGB increased from 11% to 91% at one week postoperatively and to 86% at 6 weeks. Two
rats died at 36 and 60 hours after the operation. The causes of death were unclear but the stomachs
were empty and there were no anastomotic leaks or abscesses. Another rat died during the second
postoperative week and was found to have a dilated and full gastric pouch. There were no further
deaths or complications in this group.

2.4.3 Mortality and morbidity of sham operation
Survival for the sham-operated rats was 100% at one week and dropped to 88% at 6 weeks.
One rat was euthanized at 3 weeks postoperatively for acute renal failure; necropsy revealed
bilaterally enlarged kidneys to greater than 3 times normal volume, with no dilated bladder or
pelvic abscesses.

2.4.4 Weights
After 14 weeks of high fat diet, weights of obese rats were significantly higher than
regular diet controls (473 ± 32g versus 406 ± 22g; p<0.0001). There was no statistically
significant difference in the preoperative weights of the rats that underwent RYGB or sham
operation (p=0.3). However, RYGB induced significant and sustained weight loss in the obese
rats (Figure 2.2; p<0.05 for all time points versus sham). Final mean weight at 9 weeks after
RYGB was 380 ± 60 g and after sham operation was 507 ± 34 g (p<0.001) [6].
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2.4.5 Steatosis
HFD induced steatosis after 14 weeks, increasing the number and size of fat droplets in
the liver compared with rats on a regular diet (Fig. 2.3). RYGB resulted in a decrease in
steatosis compared with sham-operated rats at 9 weeks postoperatively (Fig. 2.4). Importantly,
steatosis also improved in the rats after RYGB as compared to the same rats pre-operatively (Fig.
2.5).

2.5 Discussion
RYGB is a technically challenging procedure and is associated with high mortality in
obese rats; consequently, many investigators are not using this valuable model for studying
obesity-related diseases.
The high mortality of this model may be due to several factors. Size limitations increase
the difficulty of the procedure in small animals, with delicate tissues and large devices. The lack
of rodent-adapted devices poses a problem because even EndoGIA staplers are difficult to
maneuver into place to construct a small gastric pouch. At the same time other investigators
have noted significant failures with gastric-gastric fistulae and long operative times when using
surgical clips or handsuturing the divided stomach [4]. Additionally, rats eat anything in the
cage including bedding and feces, making preoperative fasting of the animals more challenging
and controlling postoperative diets and fluid intake more critical. Simple modifications in the
operative conduct and perioperative care of rats undergoing RYGB improved mortality in a
predictable manner.
These “specific modifications” targeted a key difference between animals and humans
undergoing the same procedure: the inability to restrain instinctive eating habits in rats. Likely,
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the most significant of these modifications was preoperative fasting of the rats in suspended wire
mesh caging, preventing the fasting rats from eating bedding or feces which both fell through the
wire mesh. After implementing this modification, we observed that the stomach was almost
always empty at the time of procedure. Surgical technique also improved with practice, but once
the learning curve had been overcome the mortality rate remained consistent over subsequent
studies, with greater than 90% survival.

2.6 Conclusions
The rat model of RYGB was successfully established and reproduced, demonstrating
sustained weight loss and resolution of steatosis after gastric bypass and identifying pertinent
interventions to improve survival for this model. This model was used by our group for all the
subsequent studies of obesity-related injury and improvements after RYGB. Lessons learned
from our experience will likely shorten the learning curve for investigators trying to establish
animal models of obesity and RYGB. Advanced surgical skills are necessary for this model and
initial high mortality should be expected by all until the learning curve has been overcome.

2.7 Note to Reader #1
Portions of this chapter (including figure 2.2) have been reproduced from Rideout DA,
Peng Y, Rakita SS, Desai K, Gower WR Jr, You M, Murr MM. Roux-en-Y gastric bypass alters
tumor necrosis factor-α but not adiponectin signaling in immediate postoperative period in obese
rats. Surg Obes Relat Dis 2010 Nov-Dec;6(6):676-80 with permission of Elsevier (see Appendix
1).
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2.8 Note to Reader #2
The animal studies were performed as part of a protocol approved by the Institutional
Animal Care and Use Committee of the University of South Florida (see Appendix 2).

Table 2.1. Rat model survival dramatically increased after implementation of surgical and perioperative interventions. Survival after RYGB increased from 11% to 91% at one week postoperatively
and to 86% at 6 weeks.

Operation Survival 1 week

Survival 6 weeks

Pre-intervention (n=18)

RYGB

11%

11%

Post-intervention (n=21)

RYGB

91%

86%

Post-intervention (n=8)

Sham

100%

88%

Figure 2.1. Rat model survival dramatically increased after implementation of surgical and perioperative interventions. Survival after RYGB increased from 11% to 91% at one week postoperatively
and to 86% at 6 weeks.
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Figure 2.2. Post-operative body weight loss after RYGB. Weight loss after RYGB was significant and
sustained (RYGB versus sham; ‡ no statistical difference at t = 0; * p<0.05 for all postoperative weeks; t
= 1-9 weeks). Final mean weight after RYGB was 380 ± 60 g and after sham operation was 507 ± 34 g
(p<0.001).
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Figure 2.3. High fat diet induced steatosis. After 14 weeks, HFD (right) increased the number and
size of fat droplets in the liver compared with rats on a regular diet (left).

Figure 2.4. RYGB improved steatosis compared with sham-operated rats. RYGB (right) decreased
the number and size of fat droplets in the liver compared with sham-operated rats (left) at 9 weeks
postoperatively.
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Figure 2.5. RYGB improved steatosis compared with the same preoperative rat. At 9 weeks after
RYGB (right) the liver had a decreased number and size of fat droplets compared with the same
rat preoperatively (left).
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Chapter 3:
Roux-en-Y Gastric Bypass Alters Tumor Necrosis Factor-α but not Adiponectin Signaling
in the Immediate Postoperative Period in Obese Rats

3.1 Overview
Adiponectin has anti-inflammatory properties and is increased with weight loss. Tumor
necrosis factor (TNF)-α is a pro-inflammatory cytokine that negatively regulates adiponectin. We
have demonstrated that Roux-en-Y gastric bypass (RYGB) induces weight loss and improves
steatosis in obese rats (see chapter 2). We hypothesized that RYGB would alter the interplay of
TNF-α and adiponectin signaling in the postoperative period.
Obese Sprague-Dawley male rats that had undergone RYGB (n=5) or sham (n=4) were
euthanized at 9 weeks postoperatively. The adiponectin levels from serial serum samples were
measured by enzyme-linked immunosorbent assay (ELISA). Adiponectin, adiponectin receptor
(AdipoR) 2, and TNF-α mRNA from adipose and liver samples were quantified by reverse
transcriptase-polymerase chain reaction (RT-PCR). Data are presented as mean ± standard
deviation; using a t test, p < 0.05 was significant.
RYGB did not change serum adiponectin, adipose tissue adiponectin mRNA, and hepatic
AdipoR2 levels compared with the levels in the sham-operated rats (p>0.05). However, the TNFα mRNA levels had decreased in adipose tissue (p<0.05) but remained unchanged in the liver
compared with the sham controls (p>0.05).
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Surgically-induced weight loss in a rat model of RYGB did not increase adiponectin
signaling in the immediate postoperative period but was associated with decreased proinflammatory signaling in the adipose tissue. During this period, pro-inflammatory signaling
might play a more important role than adiponectin.

3.2 Introduction
Obesity is a growing epidemic in the United States with significant associated comorbidities [1]. Non-Alcoholic Fatty Liver Disease (NAFLD) is a manifestation of obesity and
can lead to cirrhosis. Bariatric surgery remains the most effective anti-obesity intervention to
date and surgically induced weight loss is accompanied by remission of obesity-related comorbidities through as yet unknown mechanisms [2].
Adiponectin, an adipocyte hormone, has anti-inflammatory properties and has been
reported to increase with weight loss [3]. TNF-α is an important pro-inflammatory cytokine that
is derived from the immune cells and negatively regulates adiponectin [4]. Obesity is associated
with chronic inflammation in adipose tissue and in other organs with excess adiposity [5]. These
are important considerations because low-grade inflammatory changes have been implicated in
the pathogenesis of obesity-related cardiovascular changes and liver steatosis [5,6].
Previously, we showed that a high fat diet induces steatosis, upregulates hepatic TNF-α
signaling, and downregulates adiponectin signaling in a rodent model [7]. We have also
demonstrated that RYGB induces weight loss and improves steatosis in obese rats (see chapter
2). Therefore, we hypothesized that improvements in steatosis after RYGB in obese rats would
be associated with changes in TNF-α and adiponectin signaling in serum, adipose tissue, and
liver tissue.
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3.3 Materials and Methods

3.3.1 Animals and animal care
The animal studies were performed as part of a protocol approved by the Institutional
Animal Care and Use Committee of the University of South Florida (see Appendix 2). We
purchased 4-week old male Sprague Dawley rats from Harlan Laboratories (Harlan Sprague
Dawley, Inc., Indianapolis, IN, USA). The rats were maintained in sterile cages with appropriate
food, water, bedding, cyclical lighting (12-hour light/12-hour dark), and temperature control (2024C).

3.3.2 High fat diet
The rats were acclimated for 4 days on regular rat chow (6% fat by weight; Harlan Teklad
Global Diet 2018, Harlan Laboratories, Indianapolis, IN) and then the baseline body weights were
obtained. The rats were then randomized to regular chow or high-fat diet (60.3% of calories from
fat; Harlan Teklad TD.06414, Harlan Laboratories, Indianapolis, IN) and were maintained on their
respective diets for 14 to 16 weeks. The obese rats that were fed high-fat diet were randomized to
RYGB (n=5) or a sham operation (n=4).

3.3.3 RYGB and sham operation
The RYGB, sham operation, and perioperative care were conducted as previously
described (see chapter 2). In brief, the rats were fasted overnight and housed in suspended wire
mesh caging. The rats were anesthetized with isoflurane and given subcutaneous Ceftriaxone
(25mg/kg) and Ketoprofen (5mg/kg). A small gastric pouch (20% of the stomach) was fashioned
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using a linear stapler (EndoGIA 45-2.5; Covidien, New Haven, CT), the proximal jejunum was
divided 10 cm distal to the ligament of Treitz, and an end-to-side gastrojejunostomy was
constructed on the anterior surface of the gastric pouch using a continuous 6-0 polypropylene
suture. The jejunojejunostomy was constructed 10 cm distal to the gastrojejunostomy with
interrupted 6-0 polypropylene suture.

The sham operations were conducted with identical

perioperative care, operative conditions, and mean anesthesia times. Additionally, the abdominal
organs were mobilized and manipulated to parallel the RYGB procedure.
Postoperatively, the rats were singly housed in the suspended wire mesh cages for 7 days,
until the resumption of solid chow. An appropriate analgesic (Ketoprofen) and subcutaneous 0.9%
normal saline were given as indicated. The diets were advanced from water to dilute liquid food
(Ensure, Abbott Laboratories, Chicago, IL) to a solid high fat diet as tolerated.

3.3.4 Serum processing
Blood samples were obtained serially before and every other week after the procedure by
way of saphenous or femoral vein puncture. The blood samples were placed on ice then
centrifuged at 6,000 rpm for 8 minutes at 4C. The serum was removed and stored at -80C.

3.3.5 Tissue processing
Study-related biopsies (liver, abdominal wall muscle, subcutaneous and omental adipose)
were collected at the time of the initial operation and at 9 weeks postoperatively after
stabilization of weight loss and body weights. The samples were prepared for nuclear extraction,
placed in 10% formalin, or snap frozen in liquid nitrogen and stored at -80C.
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Total RNA was purified from frozen tissue according to manufacturer’s protocol for
adipose (RNeasy Lipid Tissue Mini Kit; Qiagen, Valencia, CA) or liver tissue (RNeasy Plus
Mini Kit; Qiagen, Valencia, CA). cDNA was prepared using random hexamers with the
SuperScript III First-Strand Synthesis System for RT-PCR (Invitrogen, Carlsbad, CA).

3.3.6 Serum adiponectin levels
The serum adiponectin levels were determined via ELISA using a CircuLex Rat
Adiponectin ELISA Kit (MBL Interntational, Woburn, MA) according to the manufacturer’s
protocol (CycLex, Japan).

3.3.7 PCR analysis
Semi-quantitative PCR analysis was used to determine the adipose adiponectin mRNA
levels. Adipose cDNA production was amplified in the presence of rat-specific adiponectin and
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (Applied Biosystems, United Kingdom)
primers for 25 cycles of PCR in a UNO-Thermo block (Biometra, Tampa, FL). The PCR
products were separated with electrophoresis in 2% agarose gel, photographed digitally (UVP,
GDS 8000 Upland, CA), and quantified by densitometry.
Quantitative real-time PCR was used to determine adipose TNF-α and hepatic TNF-α and
AdipoR2 mRNA levels using the ABI Prism 7900HT Sequence Detection System and
normalized to GAPDH (Applied Biosystems). TaqMan Gene Expression Assays, including
primer and probe were used for AdipoR2, TNF-α, and GAPDH (Applied Biosystems). The
results are expressed as relative change compared with an internal control.
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3.3.8 Statistical analysis
All data are presented as mean ± standard deviation. The 2-tailed t-test was used when
comparing two separate groups (as in RYGB and sham groups); p < 0.05 considered significant.
For serial time points (as in preoperative and postoperative), the paired t-test was utilized. When
three or more groups were compared an analysis of variance (ANOVA) was used. If the null
hypothesis was rejected by ANOVA, then the Tukey-Kramer Multiple Comparison Test was
used to determine between which groups the significant differences existed.

3.4 Results

3.4.1 Weight loss
After RYGB, this cohort of obese rats lost more weight than did the sham-operated obese
rats. The weight loss was precipitous in the first few days after RYGB and reached a nadir at 2
weeks. Subsequently, as oral intake increased, the body weight increased and had stabilized by
the sixth to seventh week. The sham-operated rats had a lesser nadir and progressively gained
weight up to the endpoint of the study at 9 weeks (p<0.05 for all post-procedure time points versus
sham; see Fig. 2.2). The mean weight at 9 weeks after RYGB was 380 ± 60 g compared to 507 ±
34 g for the obese sham controls (p<0.001).

3.4.2 Serum adiponectin
The serum adiponectin levels did not change after RYGB compared with the preoperative
levels in the same group of obese rates (p> 0.05; Fig. 3.1). Additionally, the serum adiponectin
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levels after RYGB were not different from those of the sham obese controls (14.7 ± 2.8 ng/ml
versus 15.0 ± 1.7 ng/ml; p> 0.05 at 9 weeks; Fig. 3.1).

3.4.3 Adipose and hepatic adiponectin
The adipose tissue adiponectin mRNA levels after RYGB were not different from those of
the sham-operated obese controls (1,160 ± 290 versus 1,440 ± 250; p>0.05 versus sham;
densitometry using semi-quantitative PCR; Fig. 3.2). The hepatic levels of AdipoR2 were also not
significantly altered (0.92 ± 0.29 versus 1.31 ± 0.19; p>0.05 versus sham; RQ using RT-PCR; Fig.
3.3).

3.4.4 Adipose and hepatic TNF-α
The TNF-α mRNA levels decreased in the adipose tissue (0.99 ± 0.45 versus 1.81 ± 0.43;
p<0.05 versus sham; RQ using RT-PCR; Fig. 3.4) and remained unchanged in the liver (1.56 ±
0.63 versus 1.58 ± 0.54; p>0.05 versus sham; Fig. 3.4).

3.5 Discussion
Obesity is associated with subacute chronic inflammation, hepatic steatosis and insulin
resistance [5]. Obesity activates several signaling pathways that target pro-inflammatory genes,
including the upregulation of the toll-like receptor 4/nuclear factor kappa B/TNF-α signaling
pathway [6,7]. Hepatic steatosis is associated with inflammation that results in local and
systematic insulin resistance via activation of NF-κB [8].
RYGB improves histological features of fatty liver such as steatosis and steatohepatitis
and reduces inflammatory changes in humans [9,10]. Surgically-induced weight loss in a rat
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model of RYGB similarly exhibited an antilipogenic profile by improving liver steatosis (see
chapter 2). In an attempt to investigate the early effects of RYGB on changes in the chronic
inflammatory state associated with obesity, we examined the expression of the predominant antiinflammatory adipocytokine (adiponectin) and the pro-inflammatory cytokine (TNF-α).
TNF-α is a key pro-inflammatory cytokine produced in multiple tissues including adipose
tissue. Additionally, TNF-α is known to play a significant role in liver injury through Kupffer
cell activation [11]. Its role in the pathogenesis of other inflammatory conditions such as acute
pancreatitis, trauma and sepsis has been well described [12-14].
Adiponectin is a 30-kDa protein hormone secreted by adipose tissue and known to have
anti-inflammatory and antidiabetic properties [15]. Adiponectin plays a central role in fatty acid
metabolism and has a protective role in alcoholic liver injury [4]. In humans, obesity is
associated with hypoadiponectemia [16]. Two major adiponectin receptors have been identified,
AdipoR1 and AdipoR2, with the later predominantly expressed in the liver [4]. We
demonstrated that both adiponectin and its associated hepatic receptor, AdipoR2, are decreased
in high fat diet–induced obesity in mice [7].
Adiponectin and TNF-α appear to be related, exerting opposite effects and suppressing
each others’ gene expression and production [4]. Adiponectin inhibits toll-like receptor (TLR)mediated nuclear factor kappa-B (NF-κB) signaling and cytokine production in mouse peritoneal
macrophages [17]. The serum levels of adiponectin and TNF-α have been shown to be inversely
related in ethanol-fed animal models [4]. In mice with steatohepatitis, the administration of
adiponectin reduced steatosis, attenuated inflammatory changes in the liver, and suppressed
hepatic and serum levels of TNF-α [18]. These studies suggest that adiponectin and TNF-α
signaling is important in the pathogenesis of steatosis and steatohepatitis.
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Because TNF-α is increased and adiponectin is decreased in obesity and because RYGB
improves steatosis, we hypothesized that RYGB might improve obesity-related inflammation by
altering TNF-α and adiponectin. However, we found that anti-inflammatory adiponectin
signaling, including adiponectin protein, mRNA, and receptor AdipoR2, was not changed after
RYGB in obese rats compared with sham-operated obese controls.
These data appear to contradict published data which indicates that levels of adiponectin
increase after gastric bypass [3]. One possible explanation for these results is that although
adiponectin mRNA and total adiponectin levels are not changed after RYGB, high-molecularweight multimers of adiponectin that are thought to be clinically significant are still increased
[19]. To examine this further, we can use newly-developed ELISA kits capable of measuring
serum adiponectin multimers. Another less likely explanation is that the inflammatory changes
in the early postoperative period related to either the liver biopsies or the bypass operation itself
might have masked the changes from weight loss. Although the sham procedure should have
accounted for these variables, we believe that longer follow-up after RYGB might allow for
these inflammatory changes to resolve and the long term effects of RYGB on adiponectin to be
better evaluated.
Nonetheless, RYGB decreased pro-inflammatory signaling in adipose tissue in the early
postoperative period compared with sham-operated obese controls, indicating an earlier effect of
RYGB on improving inflammation first through downregulating pro-inflammatory pathways
(TNF-α), and possibly only later, by upregulating anti-inflammatory adiponectin signaling.
Our finding that hepatic TNF-α did not change after RYGB compared with shamoperated obese controls might be in agreement with our findings from other studies where we
demonstrated that RYGB improves the histological features of steatosis and reduces oxidative
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stress and downregulates NF-κB signaling in the rat liver [20]. Although NF-κB is well-known
to downregulate TNF-α within Kupffer cells, the missing link might be the absence of increased
adiponectin at this particular time point of the study [12].
The present study had several limitations that can be addressed in our ongoing research
endeavors. This was a pilot study with relatively small group sizes. To further delineate whether
the changes after RYGB are related to food consumption, weight loss, or the bypass itself, we
need to increase the number of animals and add pair-fed and weight restricted control groups in
subsequent studies. Short-, intermediate-, and long-term postoperative points will help elucidate
the longitudinal changes after RYGB.
Notwithstanding, the results of this present study demonstrate exciting and novel changes
in the balance of pro-inflammatory (TNF-α) and anti-inflammatory (adiponectin) signaling after
RYGB and have laid the framework for future investigations into the metabolic effects of gastric
bypass on non-alcoholic fatty liver disease.

3.6 Conclusions
Surgically-induced weight loss in a rat model of RYGB does not increase the antiinflammatory adiponectin signaling in the immediate postoperative period but is associated with
decreased pro-inflammatory signaling in adipose tissue. During this period pro-inflammatory
signaling may play a more important role than adiponectin. Additional studies with longer followup are necessary to determine if adiponectin plays a role in weight loss and improvement of
steatosis after RYGB.
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3.7 Note to Reader #1
Portions of this chapter (including figures) have been reproduced from Rideout DA, Peng
Y, Rakita SS, Desai K, Gower WR Jr, You M, Murr MM. Roux-en-Y gastric bypass alters tumor
necrosis factor-α but not adiponectin signaling in immediate postoperative period in obese rats.
Surg Obes Relat Dis 2010 Nov-Dec;6(6):676-80 with permission of Elsevier (see Appendix 1).

3.8 Note to Reader #2
The animal studies were performed as part of a protocol approved by the Institutional
Animal Care and Use Committee of the University of South Florida (see Appendix 2).
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Figure 3.1. Serum adiponectin levels after RYGB. Serum adiponectin levels did not change after
RYGB at 3, 5, or 9 weeks in the same cohort of preoperative obese rats (all p> 0.05). Serum adiponectin
levels after RYGB were not different from sham controls (14.7 ± 2.8 ng/ml versus 15.0 ± 1.7 ng/ml;
p>0.05 for RYGB versus sham at 9 weeks).

39

Adiponectin mRNA

20
15
10
5
0

Sham

RYGB

Figure 3.2. Tissue adiponectin levels after RYGB. RYGB did not significantly alter adipose tissue
adiponectin mRNA levels compared with sham-operated obese controls (1,160 ± 290 versus 1,440 ± 250;
densitometry using semi-quantitative PCR; p>0.05 versus sham).
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Figure 3.3. Hepatic AdipoR2 receptor levels after RYGB. RYGB did not significantly change hepatic
AdipoR2 receptor mRNA levels compared with sham-operated obese controls (0.92 ± 0.29 versus 1.31 ±
0.19; RQ using RT-PCR; p>0.05 versus sham).
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Figure 3.4. TNF- α levels after RYGB. RYGB decreased TNF- α mRNA levels in adipose tissue
compared with sham-operated obese controls (0.99 ± 0.45 versus 1.81 ± 0.43; RQ using RT-PCR; p<0.05
versus sham) but did not alter TNF- α mRNA levels in the liver (1.56 ± 0.63 versus 1.58 ± 0.54; p>0.05
versus sham).
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Chapter 4:
Roux-en-Y Gastric Bypass Improves Steatosis by Downregulating Lipogenesis without
Upregulating Fatty Acid Oxidation in Obese Rats

4.1 Overview
We have demonstrated that Roux-en-Y gastric bypass (RYGB) decreased body weight and
improved histological features of steatosis in a rat model of obesity (see chapter 2). The molecular
mechanisms by which surgically-induced weight loss exerts its lipid-lowering effects in the liver
remain unclear. Because RYGB improves steatosis, we hypothesized that either lipogenesis would
be down-regulated or fatty acid oxidation would be upregulated or both of these would occur. We
aimed to examine major cell signaling pathways of hepatic lipogenesis and fatty acid oxidation
using our rat model of RYGB.
Obese Sprague-Dawley male rats underwent RYGB (n=9) or sham (n=4). Serum and liver
samples were obtained at 9 weeks postoperatively. Serum leptin was measured by enzyme-linked
immunosorbent assay (ELISA). Liver tissue was processed for triglyceride quantification, reverse
transcriptase-polymerase chain reaction (RT-PCR), and western blotting. Gels were quantified
using densitometry. Data are presented as mean ± standard deviation; using a t test, p < 0.05 was
significant.
RYGB reduced hepatic triglyceride and serum leptin levels compared with the levels in the
sham-operated rats. With respect to lipogenesis, steady state levels of liver mRNA did not change
significantly after RYGB for lipogenic enzymes fatty acid synthase (FAS), acetyl-CoA
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carboxylase (ACC), and gylcerol-3-phosphate acyltransferase (GPAT)-1. However, liver mRNA
for stearoyl-CoA desaturase (SCD)-1, the rate-limiting catalyst in the synthesis hepatic
triglycerides, did decrease after RYGB. Furthermore, liver SCD1 protein levels additionally
decreased as confirmed by immunoblotting. Steady state levels of liver mRNA for the SCD1
nuclear transcription factors sterol regulatory element-binding protein (SREBP)-1c and
carbohydrate regulatory element-binding protein (ChREBP) decreased after RYGB. Liver mRNA
for liver X receptor (LXR)-α, which directly targets both ChREBP and SREBP1c, significantly
decreased as well compared with the sham controls.

This demonstrates a significant

downregulation of hepatic lipogenesis after RYGB (Table 4.1).
In regards to fatty acid oxidation, surprisingly RYGB decreased steady state levels of liver
mRNA for the master metabolic controller SIRT (sirtuin)-1 compared with the sham controls.
Liver mRNA for transcription factor peroxisome proliferators-activated receptor (PPAR)-α and its
coactivator PPAR gamma coactivator (PGC)-1α did not change after RYGB. Liver mRNA levels
were decreased for both medium chain acyl CoA dehydrogenase (MCAD) and pyruvate
dehydrogenase kinase (Pdk)-4. These important enzymes for fatty acid oxidation and utilization
that are targeted by PGC1α. This demonstrates that fatty acid oxidation is not upregulated in this
rat model of RYGB.
Weight loss after RYGB in obese rats is associated with an anti-lipogenic environment in
the liver. RYGB resolves steatosis, reduces hepatic triglycerides, and downregulates hepatic
lipogenesis controlled by the SCD1 signaling pathway. This novel finding is important since
SCD1 plays a pivotal role in triglyceride synthesis. In this model, the SIRT1-PPARα/PGC1α
signaling pathway and fatty acid oxidation were not upregulated at nine weeks after RYGB.
Whether this fatty acid oxidation pathway plays a greater role at a different time point after RYGB,
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warrants further investigation.

These findings indicate that RYGB improves steatosis by

downregulating lipogenesis without upregulating fatty acid oxidation in obese rats.

4.2 Introduction
As previously stated, obesity is a major epidemic in the United States and is associated
with multiple metabolic derangements [1,2]. NAFLD is linked to the metabolic syndrome [3] and
has a nationwide prevalence of 17-33% [4], with at least 31% of bariatric surgery patients already
exhibiting advanced liver disease [5].

RYGB has been found to improve these hepatic

abnormalities [6,7] through unknown mechanisms. Having established a rat model of RYGB with
endpoints of sustained weight loss and the resolution of steatosis, we have a unique opportunity to
clarify the mechanisms and molecular pathways involved in the resolution of NAFLD.
Steatosis seems result from an imbalance of lipogenesis (production and deposition of fatty
acids) and fatty acid oxidation (breakdown and ultimately utilization of fatty acids). SCD1, FAS,
ACC, and GPAT1 are lipogenic enzymes that are upregulated in livers of obese mice [8]. SCD1
is the rate-limiting catalyst in the synthesis of monounsaturated fatty acids, a precursor for hepatic
triglycerides [9]. Given its importance, it is helpful to clarify whether cellular signaling related to
SCD1 is altered after RYGB.
Serum leptin negatively regulates hepatic SCD1 [10]. SREBP1 and ChREBP are key
nuclear transcription factors regulating the lipogenic enzymes: SCD1, FAS, ACC, and GPAT1
[9,11-13]. LXRα is a nuclear transcription factor that directly targets both SREBP1c and ChREBP
[9,14].
There is certainly interplay between lipogenesis and fatty acid oxidation. AMPK (AMPactivated kinase) regulates cellular metabolism [15], affecting both lipogenesis (by
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downregulating GPAT1) [11] and fatty acid oxidation (by upregulating PGC1α and PGC1α
targets) [16].
SIRT1 (a NAD+ - dependent deacetylase) is linked to both lipogenesis (through SREBP1)
and fatty acid oxidation through its ability to stimulate the transcription factor PPARα and to
activate PGC1α [17]. SIRT1 positively regulates PPARα and is required to activate PGC1α [18].
MCAD and Pdk4 are important enzymes for fatty acid oxidation and utilization that are targeted
by PGC1α [16].
While the signaling for key lipogenic (SCD1, FAS, ACC, and GPAT1) and fatty acid
oxidation (AMPK, PGC1α) pathways has been studied using rodent models, the molecular
mechanisms by which RYGB improves steatosis is unknown. Because RYGB improves NAFLD,
we hypothesized that either lipogenesis will be down-regulated or fatty acid oxidation will be
upregulated or both of these will occur.

4.3 Materials and Methods

4.3.1 Animals and animal care
The animal studies were performed as part of a protocol approved by the Institutional
Animal Care and Use Committee of the University of South Florida (see Appendix 2). We
purchased 4-week old male Sprague Dawley rats from Harlan Laboratories (Harlan Sprague
Dawley, Inc., Indianapolis, IN, USA). The rats were maintained in sterile cages with appropriate
food, water, bedding, cyclical lighting (12-hour light/12-hour dark), and temperature control (2024C).
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4.3.2 High fat diet
The rats were acclimated for 4 days on regular rat chow (6% fat by weight; Harlan Teklad
Global Diet 2018, Harlan Laboratories, Indianapolis, IN) and then the baseline body weights were
obtained. The rats were then randomized to regular chow or high-fat diet (60.3% of calories from
fat; Harlan Teklad TD.06414, Harlan Laboratories, Indianapolis, IN) and were maintained on their
respective diets for 14 to 16 weeks. The obese rats that were fed high-fat diet were randomized to
RYGB (n=5) or a sham operation (n=4).

4.3.3 RYGB and sham operation
The RYGB, sham operation, and perioperative care were conducted as previously
described (see chapter 2). In brief, the rats were fasted overnight and housed in suspended wire
mesh caging. The rats were anesthetized with isoflurane and given subcutaneous Ceftriaxone
(25mg/kg) and Ketoprofen (5mg/kg). A small gastric pouch (20% of the stomach) was fashioned
using a linear stapler (EndoGIA 45-2.5; Covidien, New Haven, CT), the proximal jejunum was
divided 10 cm distal to the ligament of Treitz, and an end-to-side gastrojejunostomy was
constructed on the anterior surface of the gastric pouch using a continuous 6-0 polypropylene
suture. The jejunojejunostomy was constructed 10 cm distal to the gastrojejunostomy with
interrupted 6-0 polypropylene suture.

The sham operations were conducted with identical

perioperative care, operative conditions, and mean anesthesia times. Additionally, the abdominal
organs were mobilized and manipulated to parallel the RYGB procedure.
Postoperatively, the rats were singly housed in the suspended wire mesh cages for 7 days,
until the resumption of solid chow. An appropriate analgesic (Ketoprofen) and subcutaneous 0.9%
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normal saline were given as indicated. The diets were advanced from water to dilute liquid food
(Ensure, Abbott Laboratories, Chicago, IL) to a solid high-fat diet as tolerated.

4.3.4 Serum processing
Blood samples were obtained serially before and every other week after the procedure by
way of saphenous or femoral vein puncture. The blood samples were placed on ice then
centrifuged at 6,000 rpm for 8 minutes at 4C. The serum was removed and stored at -80C.

4.3.5 Tissue processing
Study-related biopsies (liver, abdominal wall muscle, subcutaneous and omental adipose)
were collected at the time of the initial operation and at 9 weeks postoperatively after
stabilization of weight loss and body weights. The samples were prepared for nuclear extraction,
placed in 10% formalin, or snap frozen in liquid nitrogen and stored at -80C.
Total RNA was purified from frozen tissue according to manufacturer’s protocol for liver
tissue (RNeasy Plus Mini Kit; Qiagen, Valencia, CA). cDNA was prepared using random
hexamers with the SuperScript III First-Strand Synthesis System for RT-PCR (Invitrogen,
Carlsbad, CA).

4.3.6 Liver histology
Rat liver tissue fixed in 10% formalin and later embedded in paraffin, was processed for
immunofluorescent, Hematoxylin and Eosin (Harris protocol), or Oil Red O staining. Sections
were coded and evaluated by 3 independent researchers who were blinded to the animal’s
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identity. Liver sections were graded for hepatocellular ballooning and fat deposition within a
high power field.

4.3.7 Hepatic triglyceride quantification
Frozen liver samples were homogenized in radioimmune precipitation (RIPA) lysis
buffer with 0.5 M NaOH. Lipids were extracted using chloroform/methanol (2:1) per Folch
method [19]. The lipid phase was dried in a vacuum desiccator and then dissolved in 5% bovine
serum albumin. Protein concentration was checked using a Protein Assay Kit (Bio-Rad
Laboratories, Hercules, CA). Triglyceride levels were quantified using a Serum Triglyceride
Determination Kit (Sigma Chemical Company, St. Louis, MO).

4.3.8 Serum leptin levels
The serum leptin levels were determined via Quantikine Rat-Mouse Leptin Immunoassay
ELISA Kit (R&D Systems, Minneapolis, MN) according to the manufacturer’s protocol.

4.3.9 Hepatic mRNA analysis
Semi-quantitative PCR analysis was used to determine hepatic mRNA levels. Adipose
cDNA production was amplified in the presence of rat-specific SCD1, FAS, ACC, GPAT1, and
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (Applied Biosystems, United Kingdom)
primers for 25 cycles of PCR in a UNO-Thermo block (Biometra, Tampa, FL). The PCR
products were separated with electrophoresis in 2% agarose gel, photographed digitally (UVP,
GDS 8000 Upland, CA), and quantified by densitometry.
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Quantitative real-time PCR was used to determine hepatic mRNA levels using the ABI
Prism 7900HT Sequence Detection System and normalized to GAPDH (Applied Biosystems,
United Kingdom). TaqMan Gene Expression Assays including primer and probe were used for
SREBP1c, ChREBP, LXRα, SIRT1, PPARα, PGC1α, MCAD, Pdk4, and GAPDH (Applied
Biosystems). The results are expressed as relative change compared with an internal control.

4.3.10 Hepatic protein analysis
Frozen liver tissue was place in cell lysis buffer with a protease inhibitor, homogenized,
and centrifuged. Protein concentration was checked using a Protein Assay Kit (Bio-Rad
Laboratories). 100 micrograms of protein for each sample was used for Western blot analysis.
Samples were denatured (with beta-mercaptoethanol and heat), separated by 10% SDSPAGE, transferred to nitrocellulose membrane, and blocked for 1 hour (using 5% instant non-fat
dry milk in PBS and 0.1% Tween-20). The nitrocellulose membrane was incubated with the
primary antibody overnight at 4C and with the secondary for 3 hours at room temperature.
Bound primary antibody was detected by incubating with a secondary antibody and developing
membranes using Super Signal ECL reagent (Pierce, Rockford, IL). Gels were quantified by
densitometry.
Primarily antibodies included: AdipoR1, AdipoR2, PPARα, FASN, SCD1, SIRT (Santa
Cruz Biotechnology, Dallas, TX), TLR4 (BD Biosciences), pAMPKα, AMPK, pNF-kB,
SREBP1c, ChREBP, LXRα, B-actin for loading control, Histone1 for nuclear loading control
(Cell Signaling Technology, Danvers, MA). Anti-goat or anti-rabbit secondary antibodies were
used as appropriate.
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4.3.11 Statistical analysis
All data are presented as mean ± standard deviation. The 2-tailed t-test was used when
comparing two separate groups (as in RYGB and sham groups); p < 0.05 considered significant.
For serial time points (as in preoperative and postoperative), the paired t-test was utilized. When
three or more groups were compared an analysis of variance (ANOVA) was used. If the null
hypothesis was rejected by ANOVA, then the Tukey-Kramer Multiple Comparison Test was
used to determine between which groups the significant differences existed.

4.4 Results

4.4.1 Weight loss
After RYGB, this cohort of obese rats lost more weight than did the sham-operated obese
rats. The weight loss was precipitous in the first few days after RYGB and reached a nadir at 2
weeks. Subsequently, as oral intake increased, the body weight increased and had stabilized by
the sixth to seventh week. The sham-operated rats had a lesser nadir and progressively gained
weight up to the endpoint of the study at 9 weeks (p<0.05 for all post-procedure time points versus
sham; Fig. 2.2). The mean weight at 9 weeks after RYGB was 380 ± 60 g compared to 507 ± 34 g
for the obese sham controls (p<0.001).

4.4.2 Steatosis improvement
As previously demonstrated, HFD induced steatosis after 14 weeks, increasing the
number and size of fat droplets in the liver compared with rats on a regular diet (Fig. 2.3).
RYGB resulted in a decrease in steatosis compared with sham-operated rats at 9 weeks
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postoperatively (Fig. 2.4). Remarkably, the liver after RYGB appeared similar to rats of the
same age on a regular diet (Fig. 4.1). Importantly, steatosis also improved in the rats after
RYGB as compared to the same rats pre-operatively (Fig. 2.5).
To better quantify the improvement in the steatosis, hepatic triglyceride levels were
measured at 9 weeks postoperatively. Rats that had undergone RYGB demonstrated reduced
hepatic triglyceride levels when compared with the sham-operated rats (1.3 ± 0.9 versus 2.9 ± 0.5
mg triglycerides per 100 mg liver tissue; p<0.005; Fig. 4.2). Regular diet rats had 2.7 ± 0.4 mg
triglycerides per 100 mg liver tissue.

4.4.3 Serum leptin
The serum leptin levels were reduced in the rats that had undergone RYGB levels when
compared with the sham-operated rats (784 ± 535 pg/ml versus 2802 ± 1164 pg/ml; p<0.05; Fig.
4.3). This is consistent with finding in humans after RYGB. Regular diet rats had 2244 ± 778
pg/ml serum.

4.4.4 Hepatic lipogenesis
Steady state levels of liver mRNA did not change significantly after RYGB for FAS (121
± 36 versus 100 ± 50; densitometry using semi-quantitative PCR), ACC (1187 ± 164 versus 951 ±
199), or GPAT1 (620 ± 134 versus 586 ± 167); all p>0.05 versus sham; (Fig. 4.4). However, liver
SCD1 mRNA did decrease significantly after RYGB (502 ± 131 versus 1169 ± 179; p<0.01 versus
sham; Fig. 4.4); furthermore liver SCD1 protein levels also decreased after RYGB as confirmed
by immunoblotting (1023 ± 115 versus 1442 ± 110; densitometry; p<0.001 versus sham; Fig. 4.5).
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Further investigating the SCD1 signaling pathway, the steady state levels of liver mRNA
decreased after RYGB for the SCD1 nuclear transcription factors SREBP1c (1.0 ± 0.3 versus 2.8
± 0.5; RQ using RT-PCR) and ChREBP (0.9 ± 0.3 versus 2.1 ± 0.5) when compared to shamoperated rats. Liver mRNA for LXRa, which directly targets both ChREBP and SREBP1c,
significantly decreased as well (0.9 ± 0.2 versus 1.4 ± 0.1), demonstrating a downregulation of this
lipogenic pathway. All data are p<0.05 versus sham (Fig. 4.6; Table 4.1)

4.4.5 Hepatic fatty acid oxidation
RYGB was associated with decreased steady state levels of liver mRNA for SIRT1
compared with sham-operated rats (1.05 ± 0.19 vs. 1.75 ± 0.33; RQ using RT-PCR; p<0.005; Fig
4.7). Liver mRNA for PPARa and its coactivator PGC1a, did not change after RYGB (PPARa:
0.85 ±0.39 versus 1.33 ± 0.91; PGC1a: 1.12 ± 0.36 versus 1.18 ± 0.85; all p>0.05 versus sham;
Fig. 4.8). Liver mRNA levels were decreased after RYGB for PGC1a targets including MCAD
(involved in fatty acid oxidation; 0.94 ±0.18 versus 1.97 ± 0.23; p<0.0005 versus sham) and Pdk4
(involved in fatty acid utilization; 0.76 ± 0.25 versus 1.64 ± 0.50; p<0.05 versus sham) (Fig. 4.9).
This demonstrates that the fatty acid oxidation pathway is not additionally upregulated at 9 weeks
postoperative in RYGB rats when compared to sham-operated rats.

4.5 Discussion
Obesity is associated with inflammation, hepatic steatosis and insulin resistance [20].
RYGB in humans results in significant reduction in steatosis, steatohepatitis, and inflammatory
changes [21-23], but the mechanism are poorly understood. High fat diet induces obesity and
steatosis in obese rats. Surgically-induced weight loss in our rat model of RYGB exhibited an
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anti-lipogenic profile by improving liver steatosis, providing a unique opportunity to clarify the
mechanisms and molecular pathways involved in the resolution of NAFLD.
One theory of the pathogenesis of NAFLD proposes a dysfunction in both lipid metabolism
and oxidative stress. Lipids first accumulate in the liver via increased lipogenesis and fat
deposition or via decreased B-oxidation of fatty acids [24,25]. Metabolic and environmental
stressors then activate Kupffer cells and hepatic stellate cells, leading to further hepatic injury
[24,25].
Previously, using this rat model we had demonstrated sustained weight loss (paralleling
human RYGB postoperative weight curves) and the resolution of hepatic steatosis after RYGB
(see chapter 2).

The improvement in steatosis was further confirmed here by histological

improvement and a reduction in hepatic triglyceride levels after RYGB compared to shamoperated rats. Remarkably, hepatic triglyceride levels after RYGB were significantly lower than
rats at the same age who had been on a regular diet (Fig. 4.2) and not undergone any operation.
This correlates with the histological findings that after RYGB the liver demonstrated remarkable
improvement in fat deposition and hepatocellular ballooning compared to sham-operated rats and
moderate improvement over the regular diet rats. This interesting finding may indicate that rats
develop age-related steatosis and that RYGB has a protective effect against even this age-related
steatosis. This is a fascinating finding that warrants further investigation.
Because the development of steatosis is thought to be related to the imbalance of
lipogenesis and fatty acid oxidation, we decided to examine the effects of RYGB on these
pathways [24,25]. In lipogenesis, triglycerides and cholesterol are synthesized in the liver and
deposited, secreted, or utilized for other downstream processes. Lipogenic enzymes FAS and
ACC are important in the synthesis of saturated fatty acids, the building blocks for triglyceride
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synthesis [9]. SCD1, however, is the rate-limiting catalyst in the conversion of saturated fatty
acids to monounsaturated fatty acids and therefore controls the synthesis of hepatic triglycerides
[9]. While studies have shown lipogenic enzymes SCD1, FAS, ACC, and GPAT1 to be
upregulated in livers of obese mice, our rat RYGB model demonstrated that only SCD1 was
downregulated after RYGB. This is a novel finding and may provide a key to the mechanism by
which RYGB improves steatosis.
Because it appeared that SCD1 was an important component in the resolution of NAFLD
after RYGB, we investigated known regulators of SCD1. We started by measuring serum leptin,
an adipokine known to negatively regulate hepatic SCD1 [10]. In this model, the serum leptin
levels were reduced in the rats that had undergone RYGB levels when compared with the shamoperated rats. This is consistent with finding in humans after RYGB. However, given the
simultaneous decrease in both leptin and SCD1 after RYGB, it is more likely that the reduction of
hepatic SCD1 expression may be mediated by a leptin-independent mechanism.
There are a few nuclear transcription factors that are known to regulate SCD1 in the
triglyceride synthesis process. SREBP1c is a nuclear transcription factor that positively regulates
SCD1. It binds to SREBP1 response element of the SCD1 promoter and mediates the effects of
insulin on lipogenesis [9,10,12,14]. ChREBP is a nuclear transcription factor that also positively
regulates SCD1. It, however, mediates the effects of glucose on lipogenesis [9,13]. LXRα is a
ligand-activated nuclear transcription factor that directly targets both SREBP1c and ChREBP
[9,14]. It additionally binds directly to the SCD1 promoter. In this rat model, SREBP1c, ChREBP,
and LXRα were all found to be downregulated after RYGB compared with sham-operated rats.
These novel findings of the downregulation of multiple components of hepatic lipogensis, indicate
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that the SCD1 signaling pathway may be an important contributor to the beneficial effects of
RYGB on Non-Alcoholic Fatty liver Disease.
Having demonstrated the novel finding of the downregulation of hepatic lipogenic
signaling after RYGB, we focused our attention on elucidating changes in the hepatic fatty acid
oxidation pathways in this model. MCAD is an enzyme important for hepatic fatty acid
oxidation, while Pdk4 is an enzyme important for fatty acid utilization [16].
SIRT1 is a NAD+ - dependent deacetylase and a is master metabolic controller. It has a
protective role in alcohol fatty liver disease and regulates hepatic lipid metabolism by
downregulating lipogenesis (through deactivating SREBP1c) and upregulating fatty acid oxidation
(through its ability to stimulate the transcription factor PPARα and to activate PGC1α) [17,18].
PGC1α is necessary for PPARα activity. PPARα/PGC1α then binds to promoter sites on both
MCAD and Pdk4 leading to increased FA oxidation [18].
Upregulation of the SIRT1-PPARα/PGC1α signaling pathway and fatty acid oxidation
have been linked to improvement of steatosis in a mouse model of alcoholic liver injury [26]. In
this rat model, however, this pathway was not upregulated at the transcriptional level at 9 weeks
after RYGB. In fact, both MCAD (fatty acid oxidation) and Pdk4 (fatty acid utilization)
appeared to be downregulated at this time point after RYGB.
This study has limitations, in that small numbers of animals were utilized and only one
time point after RYGB or sham operation was examined. One explanation of this data is that
fatty acid oxidation and utilization may be upregulated immediately after RYGB to remove
lipids from the liver, while by 9 weeks after RYGB the downregulation of lipogenesis plays a
more significant role to prevent re-accumulation of hepatic triglycerides. Alternatively,
inflammation from obesity or the RYGB procedure itself may not have fully resolved at this time
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point. Inflammation, through adiponectin and TNF-α signaling, is known to influence both
lipogenesis and fatty acid oxidation through effects on SIRT1 [18]. Finally, this study only
examined changes in fatty acid oxidation signaling at the transcriptional level. Further
investigation of protein and activity levels for this pathway must be undertaken to confirm these
findings.

4.6 Conclusions
RYGB improves steatosis by downregulating lipogenesis without upregulating fatty acid
oxidation at 9 weeks after RYGB in obese rats. RYGB significantly reduced hepatic
triglycerides and downregulated hepatic SCD1 but not other prominent lipogenic enzymes. This
novel finding is important since SCD1 plays a pivotal role in triglyceride synthesis. RYGB
additionally downregulated SREBP1c, ChREBP, and LXRα which are key transcription factors
for SCD1. While it is established that leptin can suppress hepatic SCD1, our present study
demonstrated a simultaneous decrease in leptin and SCD1 after RYGB, thereby suggesting that
reduction of hepatic SCD1 expression may be mediated by a leptin-independent mechanism. In
this model, the SIRT1-PPARα/PGC1α signaling pathway and fatty acid oxidation were not
upregulated at nine weeks after RYGB. Whether this fatty acid oxidation pathway plays a
greater role at a different time point after RYGB needs to be determined to assess the temporal
relationship between gastric bypass and fatty acid oxidation changes. These novel findings
demonstrate a complex interplay of lipogenic and fatty acid oxidation signaling and warrant
further investigation to increase our insight into the impact of RYGB on NAFLD.
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4.7 Note to Reader #1
Portions of this chapter (including figures) have been reproduced from Rideout DA, Peng
Y, Rakita SS, Desai K, Gower WR Jr, You M, Murr MM. Roux-en-Y gastric bypass alters tumor
necrosis factor-α but not adiponectin signaling in immediate postoperative period in obese rats.
Surg Obes Relat Dis 2010 Nov-Dec;6(6):676-80 with permission of Elsevier (see Appendix 1).

4.8 Note to Reader #2
The animal studies were performed as part of a protocol approved by the Institutional
Animal Care and Use Committee of the University of South Florida (see Appendix 2).

Table 4.1 Effects of RYGB on weight and the hepatic triglyceride synthesis pathway. After RYGB,
there is a significant decrease in weight, liver triglycerides, and the SCD1 lipogenic pathway.

RYGB

Sham Control

392+/-73*

507+/-34

None

Severe

Liver Triglycerides (mg/100 mg liver)

1.3+/-0.9*

2.9+/-0.5

Serum Leptin (ELISA; pg/ml)

784+/-535*

2,802+/-1,164

SCD1 mRNA (semi-quantitative PCR)

502+/-131*

1,169+/-179

SCD1 protein (Western; densitometry)

1,023+/-115*

1,442+/-110

SREBP1c mRNA (RT-PCR RQ)

1.0+/-0.3*

2.8+/-0.5

ChREBP mRNA (RT-PCR RQ)

0.9+/-0.3*

2.1+/-0.5

LXRα mRNA (RT-PCR RQ)

0.9+/-0.2*

1.4+/-0.1

Weight (grams)
Steatosis (histology)

* significance at p<0.05
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Figure 4.1. Steatosis resolved after RYGB. After RYGB (right) the number and size of fat droplets in
the liver were decreased compared with sham-operated rats (middle) at 9 weeks postoperatively.
Remarkably, the liver after RYGB appeared similar to rats of the same age on a regular diet (left).

Figure 4.2. Triglycerides in the liver were reduced after RYGB. RYGB rats had reduced hepatic
triglyceride levels when compared with the sham-operated rats at 9 weeks postoperatively (1.3 ± 0.9
versus 2.9 ± 0.5 mg triglycerides per 100 mg liver tissue; p<0.005). Regular diet rats had 2.7 ± 0.4 mg

triglycerides per 100 mg liver tissue.
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Figure 4.3. Serum leptin levels were reduced after RYGB. After 9 weeks, RYGB rats had reduced
serum leptin levels when compared with the sham-operated rats (784 ± 535 pg/ml versus 2802 ± 1164
pg/ml; p<0.05). Regular diet rats had 2244 ± 778 pg/ml serum.

Figure 4.4. Hepatic stearoyl-CoA desaturase 1 mRNA level was decreased after RYGB. Hepatic
mRNA did not change significantly after RYGB for FAS, ACC, or GPAT1 (using semi-quantitative
PCR; all p>0.05 versus sham). However, SCD1 mRNA levels were significantly reduced when
compared with the sham-operated rats at 9 weeks postoperatively (502 ± 131 versus 1169 ± 179; p<0.01).
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Figure 4.5. Hepatic stearoyl-CoA desaturase 1 protein was decreased after RYGB. After 9 weeks,
RYGB rats had a reduced hepatic SCD1 protein level when compared with the sham-operated rats (1023
± 115 versus 1442 ± 110; p<0.001).

Figure 4.6. Hepatic mRNA levels of stearoyl-CoA desaturase 1 nuclear transcription factors were
reduced after RYGB. RYGB rats had reduced hepatic mRNA levels for SREBP1c, ChREBP, and LXRα
when compared with the sham-operated rats at 9 weeks postoperatively (RQ using RT-PCR; all p<0.05
versus sham).
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Figure 4.7. Hepatic mRNA level of SIRT1 was decreased after RYGB. RYGB rats had reduced
hepatic SIRT1 levels when compared with the sham-operated rats at 9 weeks postoperatively (1.05 ± 0.19
versus 1.75 ± 0.33; RQ using RT-PCR; p<0.005).

Figure 4.8. Hepatic mRNA levels of PPARα and PGC1α did not change after RYGB. After 9 weeks,
liver mRNA for PPARα and its coactivator PGC1α did not change when compared with the shamoperated rats (RQ using RT-PCR; all p>0.05).
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Figure 4.9. Hepatic mRNA levels of MCAD and Pdk4 were reduced after RYGB. Liver mRNA
levels were decreased after RYGB for PGC1α targets MCAD and Pdk4 when compared with the shamoperated rats at 9 weeks postoperatively (RQ using RT-PCR; all p<0.05).
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Figure 4.10. Proposed lipid metabolism changes after RYGB. RYGB improves steatosis by
downregulating hepatic lipogenesis through the SCD1 signaling pathway. Fatty acid oxidation is not
additionally upregulated at this timepoint.
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Chapter 5:
Summary

Obesity is a growing epidemic in the United States with significant co-morbidities. Rouxen-Y gastric bypass (RYGB) results in substantial long-term weight loss and the resolution of
obesity-related metabolic diseases.

There appears to be a weight-independent molecular

mechanism for the improvement in the metabolic diseases of obesity after gastric bypass. NonAlcoholic Fatty Liver Disease (NAFLD) is a serious manifestation of obesity which can lead to
cirrhosis. Chronic inflammation accompanies the hepatic steatosis. RYGB improves hepatic and
inflammatory anomalies, through unknown mechanisms.

The accompanying resolution of

metabolic disorders after gastric bypass gives a unique opportunity to elucidate the associated
mechanisms and molecular pathways. Using a rat model of RYGB, we endeavored to study the
signaling changes in inflammation and lipogenesis responsible for the resolution of NAFLD after
gastric bypass.
The first project was to establish a rat model of RYGB to be able to study obesity-related
liver injury. While it is ideal to study molecular changes after RYGB in humans, animal models
can provide useful preliminary data with more controlled, shorter, and less expensive studies which
can be corroborated later with human studies. Rodent models had demonstrated steatosis and
inflammatory changes that paralleled those seen in obese humans. Unfortunately, establishing a
rat model of RYGB was not an easy undertaking. Many published studies using the model had
operative survival rates as low as 10%. We initially followed published protocols for rat RYGB
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with minimal success. There certainly is a surgical technical learning curve, but even as we
mastered and streamlined these techniques, we still had repeated failures. We discussed our
dilemma with other labs around the country who were having some success with the model, but
they were unable to pinpoint the reason for their success. Remarkably, by being attentive to all
the details of the perioperative care of their RYGB rats, we identified several key differences that,
when implemented, resulted in instant improved survival for this rat model of RYGB. The most
important change that we made was to use metabolic cages from the time we fasted the rats
preoperatively until the time they were ready to resume full feeds. These cages house the bedding
underneath the meshed wire floor and allow the feces to fall through the floor so the rats cannot
eat the paper bedding or their feces. We had not anticipated the instinctive behavior of rats to eat
anything (including bedding and feces) both during preoperative fasting and when the rats were
recovering from surgery and not ready to resume feeds. This one perioperative change in our
protocol led to the overnight improvement in rat RYGB immediate postoperative survival from
11% to 91%. There are certainly other important factors in establishing the rat model of RYGB
including: learning the surgical technique, minimizing anesthetic time, developing a perioperative
feeding regiment, maintaining postoperative rat hydration with subcutaneous saline injection until
rats can tolerate enteric intake. Other groups may struggle with the surgical technique learning
curve or other aspects of the above listed key components for success. However, without the use
of metabolic cages (or a similar setup) the mortality is likely to be high. Without this discovery,
we would not have been able to establish the rat RYGB model for our group and proceed with any
of our other related investigations into NAFLD. We hope that this important discovery will help
other researchers as they attempt to establish animal models of obesity and RYGB. Having
established this rat model of RYGB with consistent survival of over 90%, we confirmed the
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endpoints of sustained weight loss and resolution of steatosis in these obese rats so that we could
use this model to further elucidate the pathogenesis of NAFLD.
Our second project was to use this rat model of RYGB to investigate the mechanisms
through which RYGB improves inflammation. It is known that obesity results in chronic systemic
and hepatic inflammation. It has also been proposed that NAFLD starts with the accumulation of
lipids in hepatocytes (steatosis) and then a second metabolic or environmental stressor (like
inflammation) leads to progression of the disease. There are two countering aspects of systemic
inflammation in the body. Adiponectin has anti-inflammatory properties and is increased with
weight loss. Tumor necrosis factor (TNF)-α is a pro-inflammatory cytokine that negatively
regulates adiponectin. In a mouse model, we had shown that high fat diet induced steatosis,
upregulated hepatic inflammatory TNF-α signaling, and downregulated adiponectin antiinflammatory signaling. We therefore thought that improvements in steatosis after RYGB in obese
rats would change the balance between TNF-α and adiponectin signaling in a beneficial manner,
decreasing the overall inflammatory state. Using our rat model of RYGB, we examined TNF-α
and adiponectin signaling in serum, adipose tissue, and liver tissue. Contrary to what we were
expecting, we found that anti-inflammatory adiponectin signaling was not increased after RYGB
in obese rats compared with sham-operated controls. Nonetheless, RYGB did decrease the TNFα pro-inflammatory signaling in adipose tissue at the particular point in the postoperative period
that we were examining. We did expect the pro-inflammatory pathway to be downregulated, but
we were additionally anticipating the anti-inflammatory signaling to be upregulated. This area
still lends itself to further investigation and it may be that the anti-inflammatory adiponectin
signaling plays a more significant role at a different time point after RYGB.
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Our final project was to use the rat model of RYGB to investigate the mechanisms through
which RYGB improves hepatic steatosis. This is where we made our most significant and novel
discoveries. We had already confirmed in this rat model of RYGB that there was sustained weight
loss and resolution of steatosis after gastric bypass. We further quantified this improvement in
steatosis by demonstrating a significant decrease in hepatic triglyceride levels when compared to
the sham-operated rats. Steatosis can be due to increase in lipogenesis (leading to increased fat
deposition in the liver) or a decrease in fatty acid oxidation or utilization (resulting in less
breakdown of the fat deposits that are already present). After gastric bypass, we wanted to
determine what cell signaling changes controlled the near resolution of steatosis in these rats. We
hypothesized that either lipogenesis would be down-regulated or fatty acid oxidation would be
upregulated or both of these would occur. We aimed to examine major cell signaling pathways of
hepatic lipogenesis and fatty acid oxidation using our rat model of RYGB. When investigating
lipogenic signaling, we discovered that lipogenic enzymes FA, ACC, and GPAT1 did not change
significantly after RYGB but SCD1 did decrease significantly. This is important because SCD1
is the rate-limiting catalyst in the synthesis hepatic triglycerides. We further examined the
regulation of SCD1 found that SCD1 nuclear transcription factors SREBP1c, ChREBP, and LXRα
were all decreased after RYGB. This demonstrates a significant downregulation of hepatic
lipogenesis via SCD1 signaling pathway as an important mechanism in the improvement of
steatosis after RYGB. Further investigation of fatty acid oxidation did not demonstrate any
additional upregulation of these pathways after RYGB.

Whether fatty acid oxidation and

utilization pathways plays a greater role at a different time point after RYGB warrants further
investigation. Our current findings indicate that RYGB attenuates obesity-related liver injury by
downregulating lipogenesis without upregulating fatty acid oxidation in obese rats. The discovery
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of the downregulation of the SCD1 mediated triglyceride synthesis pathway after RYGB is any
important discovery that can direct future investigations and hopefully lead to non-operative
options to treat NAFLD.
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bypass alters tumor necrosis factor-α but not adiponectin signaling in immediate postoperative
period in obese rats. Surg Obes Relat Dis 2010 Nov-Dec;6(6):676-80. doi:
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